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Abstract
A major challenge to our understanding of the molecular mechanisms of Alzheimer’s disease (AD) has been the
lack of physiologically relevant in vitro models which capture the precise patient genome, in the cell type of
interest, with physiological expression levels of the gene(s) of interest. Induced pluripotent stem cell (iPSC)
technology, together with advances in 2D and 3D neuronal differentiation, offers a unique opportunity to
overcome this challenge and generate a limitless supply of human neurons for in vitro studies. iPSC-neuron models
have been widely employed to model AD and we discuss in this review the progress that has been made to date
using patient-derived neurons to recapitulate key aspects of AD pathology and how these models have
contributed to a deeper understanding of AD molecular mechanisms, as well as addressing the key challenges
posed by using this technology and what progress is being made to overcome these. Finally, we highlight future
directions for the use of iPSC-neurons in AD research and highlight the potential value of this technology to
neurodegenerative research in the coming years.
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Background
It is estimated that 46.8 million people worldwide are
living with dementia, a figure that is predicted to increase
to 131.5 million by 2050 [1]. Alzheimer’s disease (AD) is
the most common cause of dementia, representing an
estimated 60–80% of total cases. Pathologically, AD is
characterised by the presence of extracellular amyloid pla-
ques composed of the amyloid beta (Aβ) peptide and
intracellular neurofibrillary tangles composed of the
microtubule associated protein tau. Understanding the
contribution of these two pathologies to disease aetiology
and neuronal death has been a focus of intense research
efforts. However, our progress in this area has been lim-
ited by the difficulties in generating in vitro and in vivo
models that recapitulate these pathologies together with
neuronal death. For example, rodent models generally rely
on the overexpression of one or more genes associated
with AD and although they can successfully recapitulate
some of the disease pathologies, this occurs in the absence
of neurodegeneration [2]. Thus, physiologically relevant
models, permitting the study of disease mechanisms in a
human genetic context, with physiological gene expression
levels and in the cell types specifically affected in disease
would be a great asset for deepening our understanding of
the molecular mechanisms of AD and the development of
novel therapeutics.
Induced pluripotent stem cells (iPSCs) offer an attract-
ive methodology to overcome these barriers in order to
generate physiologically relevant models of neurological
disease. In 2007, the exogenous introduction of a cock-
tail of pluripotency-associated transcription factors such
as OCT4, KLF4, SOX2 and c-MYC into terminally dif-
ferentiated cells such as fibroblasts was shown to be suf-
ficient to revert them to a pluripotent state,
indistinguishable from human embryonic stem cells
(hESCs) [3, 4]. The resulting iPSCs can subsequently be
differentiated into multiple cell types, including neurons.
The generation and neuronal differentiation of iPSCs
from patients with dementia therefore offer a unique
opportunity to create physiologically relevant in vitro
models for mechanistic studies and preclinical drug dis-
covery, and have been widely adopted by the field (Fig. 1)
[5]. In this review, we discuss the progress made to date
in using this approach to model AD and highlight the
challenges facing the field moving forward.
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Differentiation of iPSCs into relevant cell types
For successful disease modelling using iPSCs, it is essential
to generate the cell type affected by disease in a quick and
efficient manner with a high degree of purity. The tissues
affected early in AD include the neocortex and hippocam-
pus, primarily pyramidal, glutamatergic neurons [6].
Additionally, there is evidence that pyramidal cell innerv-
ation by cholinergic neurons is lost early in AD, defining
the basis of the cholinergic hypothesis of AD and suggest-
ing that cholinergic cells initiate AD [7]. From the neocor-
tex and hippocampus, tau pathology is seen to spread in a
defined manner that traces neuronal connectivity and
tracks disease severity [8]. Aβ accumulation focuses in the
isocortex and its progression is less predictable than tau
(reviewed in [9]). For this reason, the major goal of stem
cell differentiation in AD research is the generation of
glutamatergic, cortical neurons.
Two-dimensional adherent neuronal cultures
Directed differentiation of stem cells towards disease-
relevant neurons has gained momentum over the past
decade and protocols now routinely generate cultures with
high purity of the neuron of interest. Since the first reports
of neural specification [10, 11], information about extrin-
sic signalling conditions gleaned from developmental biol-
ogy have been applied to stem cell differentiation, leading
to defined fate choices and increasingly pure neuronal
populations (reviewed by [12]). With this in mind, stem
cell differentiation closely mirrors developmental events,
timing and signalling conditions—akin to applied develop-
mental biology.
Stem cell neurogenesis progresses through three phases:
neural induction, patterning, and terminal differentiation.
In 2D cultures, dual SMAD inhibition has been widely
adopted to enhance neural fate choice and closely mimic
signalling conditions in the early embryo [13, 14]. Follow-
ing neural commitment, human neuroepithelium has a
default differentiation potential to become cortical tissue.
This is due to an anterior neural character with high levels
of Wnt signalling, leading to dorsalisation of the cells [15].
This provides a great efficiency to cortical differentiation
protocols and can be further enhanced by inhibiting ven-
tral fates via Sonic hedgehog (SHH) antagonists [16]. At
this stage, extrinsic signalling conditions can be manipu-
lated to lead to differentiation to other cell types of inter-
est [15]. Committed neural progenitors are subsequently
allowed to undergo protracted terminal differentiation to
mature neurons, a process that follows in vivo corticogen-
esis. Protocols that are widely employed in the field follow
these defined milestones [14, 17, 18] and have been shown
to be reliant on retinoid signalling [18] and also are able
to produce cells that functionally integrate with host cir-
cuitry after transplantation into rodent models [17].
The cortex is made up of six defined neuronal layers
with characteristic identity and marker expression. In
vivo, these are generated in a time-dependent manner,
with deeper layers generated first and upper layers later.
Inhibitory interneurons migrate from ventral tissues into
Fig. 1 Stem cell applications. Schematic to depict the potential applications of stem cell technology. Patient material is reprogrammed to iPSCs
via the four reprogramming genes. Relevant advantages and disadvantages of the subsequent differentaition to cortical neurons via 2D and 3D
methods are discussed. Finally, applications for stem cell-derived neurons are depicted, namely drug screening, investigating disease mechanisms,
in vivo transplantation of neuronal material to model organisms as well as the potential for cell therapy
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the cortex, modulating the activity and development of
cortical excitatory neurons. These processes are all recapit-
ulated by differentiating stem cells in vitro, whereby upper
layer neurons are generated later in culture, necessitating
differentiation periods of 100 days in vitro to generate a
full complement of electrically active neurons [17, 18].
Recent reports have attempted to accelerate stem cell
differentiation, making the in vitro model more access-
ible. This has been achieved by either overexpression of
the pro-neural transcription factor NGN2, which gener-
ates homogeneous cortical populations in 2–3 weeks
[19] or a combination of small molecule inhibitors tar-
geting ERK, FGF, Notch and Wnt signalling pathways,
which leads to a highly pure population of functionally
active deep-layer neurons in just 13 days [20].
In addition to cortical glutamatergic neurons, proto-
cols for the directed differentiation of stem cells into
other cell types relevant to AD have been developed.
These include cortical interneurons [21, 22] and cholin-
ergic neurons [23], two cell types that have been sug-
gested to be involved in AD. Both cell types develop
from the ventral forebrain and so are dependent on ven-
tralising signals such as SHH. As in vitro models in-
crease in complexity, such as investigating the interplay
between neuronal subtypes, the employment of multiple
models will become increasingly relevant.
After extended periods in culture, neurogenic cultures
undergo a gliogenic switch, producing primarily astro-
cytes rather than neurons [24]. Treatment with mitogens,
such as FGF, and patterning molecules, such as BMP and
LIF, leads to increasingly enriched astrocyte cultures [25].
Astrocytes provide important support to neurons and are
increasingly implicated in non-cell autonomous disease
processes. These will be discussed in detail below.
The differentiation of stem cells in two dimensions
benefits from consistent extracellular conditions through-
out the culture, whereby all cells are exposed to similar
growth factor concentrations throughout the adherent
monolayer, giving great control to the user and high levels
of purity of the resultant population. This is relevant not
only for extrinsic growth factors but also for applications
such as genetic manipulation or drug screening. The
resultant cultures display electrophysiologically active
neurons, vital for studying AD processes in the cell-
relevant model. However, these cultures represent a
reductionist approach and the small number of cell
types may be seen as a drawback. Additionally, iPSC-
derived neurons have a foetal developmental age [26, 27],
necessitating careful considerations when investigating
ageing diseases such as AD.
Three-dimensional neuronal cultures
In an attempt to better model the developing brain, rigid
scaffolds have been employed to produce 3D neuronal
cultures. These are created from a variety of materials,
including, but not limited to, polydimethylsiloxane with
micrometric cavities [28], super-porous/non-porous
hydrogels, sintered titanium [29] and hydrogels or matri-
gels [30]. Mixtures of microfibre and nanofibre scaffolds
made from polymers such as poly lactic acid and
polyethylene terephthalate, respectively, enable struc-
tural integrity yet small pore size to increase cellular
adhesion [31].
Primary neurons and differentiated iPSCs have been
used in a 3D soft matrix scaffold, conferring some
advantages over 2D. Neuron bodies are more rounded
and in proximity with cells on all sides and neurites can
extend in all directions, closely modelling the axonal
architecture in vivo [28, 32].
The aforementioned support structures accomplish 3D
tissue culture in different ways. Ridged and inorganic
scaffolds serve more as support and guidance for cellular
growth, while softer encapsulating scaffolds mimic the
extracellular matrix, providing support as well as pro-
moting growth within itself [28, 33]. However, these 3D
cultures are more akin to a cell suspension within a sup-
portive matrix, rather than a fully 3D tissue.
Three-dimensional organoid cultures
Although 2D cultures and scaffolds offer the benefits
outlined above, they lack the cellular diversity, structural
complexity and physical architecture seen in vivo. Thus,
efforts to create 3D models of neurons and glia are cru-
cial for developing physiologically relevant models [34].
Neural differentiation in three dimensions follows the
same three processes as adherent monolayer protocols,
namely neural induction, patterning and terminal differ-
entiation. Upon exit from the pluripotent state, the small
size of the 3D structures, termed embryoid bodies (EBs),
enable the researcher to have close control over the
neural fate choice. Similar to 2D cultures, SMAD inhibi-
tors may be used at this stage to enhance neural fate
choice [14, 35, 36].
In contrast to differentiation in 2D, however, 3D strat-
egies allow intrinsic cell behaviour to determine the devel-
opment of the EB or organoid. Cell autonomous signals
lead to events such as migration, polarisation of neuroepi-
thelium and generation of a range of cell subtypes, cul-
minating in self-organised heterogeneous neuronal tissue.
Spatiotemporal signalling events and inherent gene cas-
cades, with inherent genetic competencies and responses
tightly controlled in time and space, strictly govern these
complex cell behaviours. This self-organising phenotype
gives 3D suspension organoids more in vivo relevance
than the scaffolded 3D tissue cultures discussed above.
Organoids have been shown to exhibit defined radial
glial cells, a cell type relevant to brain development and
higher function. These show appropriate morphology
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and organisation, being representative of the developing
human cortex [37]. Supportive cells that develop along-
side early neurons may well be vital in modelling disease
initiation and progression [38]. These events enable
complex experimental questions to be asked, such as the
cross-talk between cell types, e.g. neurons and glia. This
is a further advantage for drug discovery when support
cells may be crucial or the pathway of interest is not
known [34]. The fact that a 3D organoid more closely
resembles tissue goes some way to reducing 2D cell cul-
ture artefacts and improving the robustness of findings
in 2D cultures.
The development of organoids patterned towards the
cortex has progressed in recent years. Endogenous pat-
terning and terminal differentiation produce 3D struc-
tures with appropriate cortical cell layers and functional
neurons [39]. These structures can also be further pat-
terned to other brain regions of interest by the addition
of extrinsic growth factors, albeit the effects are seen at
the outer portions of the 3D structure [37, 40, 41].
In spite of these advances, organoids also have several
limitations. The self-organising nature by which orga-
noids are generated leads to increased heterogeneity be-
tween batches [37]. This variability between organoids
means analysis methods such as bulk-population tran-
scriptomics or western blotting on whole tissue extracts
may be difficult to interpret. However, single-cell tran-
scriptomics has successfully shown that the diversity of
cell types present in organoids closely resembles that
present in developing foetal brain [27]. This provides
confidence in the physiological relevance of the system
but once again raises the issue of developmental matur-
ity and how relevant cerebral organoids are in represent-
ing the modelling of late-onset diseases. Finally, when
organoids exceed 6–10 mm in diameter, the inability of
nutrients to penetrate the organoids results in a necrotic
centre, leading to the release of caspases and other detri-
mental cell signals, potentially increasing cell stress in
larger organoids [42]. Organoids have been successfully
kept in continuous culture for up to one year, although
some shrinkage can be observed from 6 months onward,
when the necrotic core usually starts to develop [43]. To
halt proliferation of the organoid, reducing the chance
of a necrotic core developing, inhibition of mitogenic
signals such as Notch can increase terminal differenti-
ation, which may enhance maturity [44, 45].
On a practical level, culture of cerebral organoids
within spinning flasks [46] has been shown to offer en-
hanced diffusion of nutrients and oxygen, allowing for
larger and more continuous organoid growth. However,
these large custom-made organoid systems are expensive
to purchase and require large amounts of costly media.
The development of 3D-printed bioreactors provides a
compact and economical method for organoid culture;
3D-printed bioreactors are plastic lids for standard six-
well plates that incorporate mini-stirrers attached to an
electric motor, allowing constant media movement
around the organoids. This enables users to easily adopt
them into existing cell culture facilities without the re-
quirement of accommodating large orbital shakers or
spinning bioreactors in tissue culture incubators [37].
Further, mini-bioreactors reduce heterogeneity in orga-
noids and reduces the amount of media required, redu-
cing the costs associated with organoid generation [47].
In spite of these drawbacks, organoids have been used
very successfully to model neurodevelopmental processes
and diseases, for example normal cortical folding [48],
microcephaly [30] and lissencephaly [49]. Importantly,
organoids have been used to uncover species-specific dif-
ferences between human and murine cortical develop-
ment that lead to folding and expansion in human tissues
specifically [48]. Although reports of organoid models of
neurodegenerative disease are limited at present, they have
the potential to be an insightful new model in AD
research, allowing researchers to experiment with more
heterogeneous, naturally organised 3D cell models.
iPSC-neurons in AD research
Much of what we know about the molecular mecha-
nisms of AD has been guided by our knowledge of the
genetics of disease and specifically autosomal dominant,
familial AD (fAD). Pathologically, AD is characterised by
the presence of Aβ plaques and neurofibrillary tangles.
Studies into autosomal dominant AD identified muta-
tions in amyloid precursor protein (APP), Presenilin 1
(PSEN1) and Presenilin 2 (PSEN2) that are causative of
disease, although 99% of AD is sporadic. The common-
alities in pathology between fAD and sporadic AD (sAD)
imply that studies in fAD can be broadly applicable to
AD as a whole.
APP, PSEN1 and PSEN2 have been shown to function
in a single pathway, namely APP processing, centrally
implicating this pathway in AD pathogenesis. APP is a
transmembrane protein with unknown function present
in endosomes and at the cell surface. Sequential cleavage
by either α-secretase and γ-secretase or β-secretase and
γ-secretase leads to extracellular soluble APP (sAPP),
which may function in cellular signalling, an intracellular
domain with possible cell-autonomous functions, and
small membrane fragments. The β-secretase and γ-
secretase path produces Aβ, a small peptide that was
shown to be the primary constituent of amyloid plaques.
PSEN1 and PSEN2 are alternative subunits of the γ-
secretase complex. Thus, alterations in APP processing
and Aβ imbalance are thought to lie behind AD. Much
is still to be understood about the normal function of
the γ-secretase complex (known to cleave multiple sub-
strates such as Notch, Cadherin and Ephrin as well as
Arber et al. Alzheimer's Research & Therapy  (2017) 9:42 Page 4 of 17
APP) as well as the different specificities and expression
patterns of its components. For example PSEN1 localises
throughout the cell whereas PSEN2 is restricted to the
endosome and lysosome compartments [50].
The following section discusses the relative promise
and early successes in the use of iPSC-derived cells to
model AD pathology and offer insight into disease
mechanisms.
Investigating the normal function of AD-associated proteins
in human iPSC-neurons
Human iPSC-derived neurons represent a useful tool for
studying the normal function of AD-associated proteins in
a human neuronal setting. For example, the function of
APP is yet to be fully understood, with complex splice vari-
ants, cell compartmentalisation and cell specificity
(reviewed by [51]). sAPP, the soluble fragment of APP shed
from the neuron after cleavage by α or β secretase, induces
a strong pro-differentiation effect towards the neural
lineage from hESCs [52, 53]. Premature differentiation is
also seen in iPSC-derived neural progenitors transfected
with mutant transgenic PSEN1 [54]. The Notch and Wnt
signalling pathways, which regulate neuronal development
among other cellular processes, are involved in aberrant dif-
ferentiation of these mutant PSEN1 lines.
In an elegant study, Liao and colleagues used single cell
techniques to understand the sAPPα and Aβ profiles of
individual iPSC-neurons and iPSC-astrocytes [55]. fAD
mutations did not alter the overall profiles of sAPPα and
Aβ across the population. Critically, there was no bias in
Aβ secretion towards neurons or astrocytes; however,
trends to increased secretion were present in deep layer
cortical cells and GABAergic interneurons.
These studies have applied iPSC technology to gain
new knowledge of APP and PSEN1 function in human
neurons. The physiological relevance of the cell model
enables new insights into the normal functions of these
proteins in neurons. As well as these studies into the
normal role of APP and PSEN1 in human iPSC-neurons,
a wide variety of investigations are making use of iPSC
technology. To exemplify the breadth of the model’s ap-
plication, two examples include screening for modula-
tors of APP processing in iPSC-derived neurons [56]
and iPSC-derived macrophage like cells overexpressing
the Aβ degrading enzyme Neprilysin 2 that are able to
reduce Aβ levels in culture media and the rodent brain
[57]. The scope of research into AD using iPSC-derived
neurons will be discussed in the sections below.
Investigating aggregate toxicity using iPSC-neurons
Stem cell-derived neurons have been used to investigate
cellular toxicity of Aβ oligomers [58, 59]. Employing
cortical neurons generated from control iPSCs enables
investigations into downstream signalling and toxicity
induced by exogenous AD-associated peptides in human
neurons for the first time.
Aβ was shown to bind to glutamatergic and GABAer-
gic iPSC-derived neurons but specifically led to cell
death in glutamatergic neurons [58]. Eight days of oligo-
meric Aβ treatment was shown to be sufficient to lead
to synaptotoxicity [59]. This was demonstrated via al-
tered axonal vesicle clusters, impaired postsynaptic
AMPA signalling and a resultant induction of phosphor-
ylated tau and endoplasmic reticulum (ER) stress. It
should be noted that the concentrations of Aβ sufficient
to induce cell death in these models (1–5 μM) are in ex-
cess of normal physiological levels, which are believed to
be in the low nanomolar range [60] in control tissue and
increased up to 50 nM in AD brain tissue [61].
Together, these studies have reinforced investigations
using cell lines and rodent models which demonstrate
cellular toxicity resulting from pathological spread in
AD. Synaptic loss and calcium imbalance in healthy hu-
man neurons in response to AD-associated aggregates
may hint at early pathological mechanisms.
iPSC models of fAD
The reprogramming of patient-derived cells to neurons
allows cultures of human neurons with genetic predis-
position to AD to be probed for the earliest disease
events. Not only can the direct effects of enzyme muta-
tions in fAD be used as a readout, but also sporadic
disease with undefined genetic causes or risks can be
modelled. iPSC-derived neurons are being widely
employed to study the pathological processes in AD, the
spread of pathology and also the earliest events under-
lying disease aetiology (Fig. 1).
APP processing
Several studies have now demonstrated that fAD patient-
derived iPSC-neurons display an increased Aβ42:40 ratio
and an increase in phosphorylated tau compared to con-
trol iPSC-neurons (Table 1) [62–76]. These features have
also been explored in sporadic patient-derived cells with
varied results as some lines behave as fAD and some as
control lines with respect to Aβ secretion and tau phos-
phorylation [64, 67]. The majority of these studies have
been based on cortical differentiation protocols, necessi-
tating long differentiation periods as APP expression and
Aβ peptides progressively increase from 30 days of differ-
entiation to mature cultures at 100 days [63, 71, 77].
In addition to monogenic fAD models, APP dosage
models have been shown to demonstrate similar changes
in APP processing to patients with APP duplication
[64, 78] and Down’s syndrome (trisomy of chromosome
21 on which APP resides) [65, 74].
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Drug discovery
iPSC technology offers a unique opportunity for drug
discovery. Not only can efficacy and toxicity studies be
carried out in cells such as neurons and hepatocytes, but
also reporter cell lines can be used to screen for drugs
with desired responses from large compound libraries.
For example, cells that express GFP under the NKX2.1
promoter have been employed to develop efficient dif-
ferentiation protocols to generate cortical interneurons,
a cell type dependent on NKX2.1 expression. Finding
small molecules that enhance GFP cell numbers can
then replace costly recombinant protein growth fac-
tors, as such the WNT antagonist XAV939 [22]. With
respect to AD, the accepted link between increased
Aβ42:40 ratio and dementia may become the basis of
future drug discovery platform readouts. A proof of
concept for this has been shown as γ-secretase inhibi-
tors are able to reduce total Aβ levels and Aβ42:40
ratios (Table 1) [58, 64, 69, 71, 79]. These models can
potentially reduce the load on animal efficacy studies
while also representing a human-specific model.
Similarly, β-secretase inhibitors have been shown to
reduce total levels of Aβ [63, 67] and may influence
GSK3β activity and tau phosphorylation more directly
than γ-secretase inhibitors [64]. Direct inhibition of
GSK3β (and so activation of Wnt) leads to reduced levels
of phosphorylated tau without affecting Aβ accumulation
[79]. A phthalide compound that also increases Wnt
signalling had a similar effect on tau and also reduced Aβ
levels in Down’s syndrome iPSC-neurons [74]. Longer
treatments of β-secretase inhibition in 3D models was
shown to reduce both phosphorylated tau and Aβ [78].
The effects of other drug molecules have been investi-
gated using fAD iPSC-derived neurons. Compound W, a
specific Aβ42 inhibitor, was shown to reduce the
Aβ42:40 ratio [62]. Non-steroidal anti-inflammatory
drugs (NSAIDs) are also able to reduce the Aβ42:40
ratio [63], although some PSEN1 mutations seem unre-
sponsive to NSAIDs [66].
These studies demonstrate the potential utility of
iPSC-neurons to provide a neuronal platform for toxicity
or efficacy screening that may highlight potential candi-
date molecules, although critical hurdles remain. Firstly,
off-target side effects are not evident in neuronal cell
cultures, and secondly, a drug’s ability to cross the
blood–brain barrier is not addressed in reductionist
models consisting of pure cell populations. However, the
use of this platform to narrow a drug pipeline can un-
doubtedly save pharmaceutical companies time and
money as well as increase the likelihood of finding a
potential hit. As an example of the potential success and
value of the technology, iPSC models of familial disauto-
nomia have led to clinical trials following small molecule
screens in vitro [80].
Biochemical effects of fAD mutations
The biochemical mechanisms behind the change in Aβ
ratio have been investigated using iPSC-neurons. The
A673T mutation in APP leads to a reduced likelihood of
contracting AD [81]. Using iPSCs and their isogenic
controls, Maloney and colleagues demonstrated that this
mutation leads to a reduced efficiency of β-secretase
cleavage of APP and a subsequent reduction in the
ability of mutant Aβ to form aggregates [70]. This result
reinforces the central role of Aβ in disease.
In contrast, utilising the V717I mutation in APP,
Muratore et al. [71] were able to show that mutant APP
had an increased likelihood to be cleaved by β-secretase
over α-secretase and therefore Aβ accumulated. Blocking
antibodies to Aβ were able to prevent the Aβ-associated
tau pathology in these cells, directly linking extracellular
Aβ to downstream tau phosphorylation.
The link between APP processing and tau has been
further investigated in iPSC-derived neurons. APP muta-
tions, but not PSEN1 mutations, were shown to directly
lead to increased total tau and phosphorylated tau in
iPSC-derived neurons [75]. Extended periods of γ-
secretase modulation were able to reverse these features
and hint that APP processing can influence tau in an
Aβ-independent manner.
Woodruff and colleagues made use of gene-editing tech-
nology in iPSCs to investigate the precise effect of domin-
antly inherited PSEN1 mutations in human neuronal
cultures without overexpression [76]. The authors demon-
strated that Δ exon 9 PSEN1 (ΔE9) mutations lead to re-
duced γ-secretase activity, shown via an accumulation of
unprocessed APP C-terminal fragments and altered
Aβ42:40. Importantly, these effects were seen in wild-
type/ΔE9 cells and ΔE9/null cells, but not wild-type/null
cells. These results point towards a toxic gain of function
via poisoning of the γ-secretase complex by mutant
PSEN1 protein. Interestingly γ-secretase-independent
functions of PSEN1 remain unchanged [76], shown via the
ability of cells to produce mature Nicastrin [82]. It should
be noted that some controversy remains about whether
PSEN1 mutations are gain or loss of function (see the dis-
cussion in Woodruff et al. [76]).
Novel insights into molecular mechanisms
Israel et al. [64] described aberrant swollen early endo-
somes in the soma of AD-derived neurons. Further, Aβ
was shown to accumulate in the ER, endosomal and
lysosomal compartments, leading to ER stress and react-
ive oxygen species (ROS) damage [67, 71]. In E693Δ
APP mutant neurons, which show intracellular Aβ accu-
mulation, ER and oxidative stress were shared between
AD neurons and astrocytes and reversed by drugs in-
cluding γ-secretase inhibitors and docosahexaenoic acid
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(which did not alter Aβ levels) [67]. These studies impli-
cate intracellular Aβ as an important disease modulator
and potentially the endosome as a central compartment
for APP proteolysis, a compartment to which PSEN2
and only fAD-mutant PSEN1 localise [50].
Similar cellular pathways were shown to be affected in
sAD patient-derived neurons; a reduction was observed
in the unfolded protein response, oxidative damage and
cell death pathways (pathways common to other neuro-
degenerative diseases) whereas Wnt signalling pathways
were induced [67]. Interestingly, pre-existing Aβ aggre-
gates were degraded after inhibition of β-secretase, sug-
gesting cells retain an undefined ability to degrade
accumulated Aβ. Removal of pre-existing aggregates
may be crucial to the ability of inhibitors to reverse cel-
lular stress responses and provide insights into disease
and treatment mechanisms.
The downstream mechanisms resulting from fAD
mutations have also been analysed. iPSC-derived neural
progenitors were shown to have a number of differen-
tially expressed genes when compared with healthy con-
trol cells [72]. Encouragingly, five of these genes were
also dysregulated in post-mortem brain of AD patients.
These similarities show the relevance of the in vitro
models, but also can highlight molecular pathways that
may lie upstream of pathological processes in non-aged
neurons. These include Norrin, a molecule involved in
Wnt signalling and shown by the authors to lead to re-
duced neurogenesis in the AD brain [72].
In sum, these studies have successfully employed
iPSC-derived neurons to provide new insights into AD
(summarised in Table 1).
Investigating AD risk factors using iPSC-neurons
In addition to autosomal dominant mutations in PSEN1,
PSEN2 and APP, multiple genetic variants that lead to
increased risk of late onset AD have been identified. The
APOE4 variant was initially identified in 1993 as an AD
risk factor [83]. Genome-wide association studies in
large cohorts have enabled the identification of multiple
loci associated with increased likelihood of AD. These
include CLU, CR1 and PICALM [84] and SORL1 [85]
amongst others [86–88]. Heterozygous mutations in
TREM2 were shown to increase risk of AD by one-third
[89, 90]. Importantly, the cellular mechanisms linking
these genetic loci to increased AD risk remain to be
understood. Pathways such as inflammation and the
endosome/lysosome pathway have single nucleotide
polymorphisms (SNPs) in multiple genes implicated in
AD risk, suggesting a central function of these pathways
in disease progression.
Patient-derived iPSC-neurons enable investigations
into the effects of risk-associated SNPs and mutations.
To date, four articles have described investigations into
AD risk factors utilising iPSCs derived from SNP carriers
in APOE, SORL1 and CR1 [68, 91–93].
Basal forebrain cholinergic neurons (BFCNs) have
been shown to degenerate early in AD pathogenesis
[94]. Duan et al. [68] generated BFCNs from fAD and
sporadic patients with APOE3/E4 risk genotypes. All AD
lines showed increased Aβ42:40 and glutamate-induced
vulnerability. Interestingly, one sporadic line showed in-
creased Aβ40 secretion at low concentrations of γ-secre-
tase inhibition. This is reminiscent of the variability
witnessed in other studies at low doses of inhibition [76]
or alternatively may be mutation-dependent [66].
The link between APOE genotype and APP was fur-
ther investigated using ESC-derived neurons by Huang
et al. [92]. The authors show that APOE stimulates APP
production in neurons, and subsequently Aβ, via MAPK
signalling. The AD risk factor APOE4 stimulates more
APP and Aβ production than the common allele
APOE3, and the protective allele APOE2 induces the
lowest APP protein production [92]. This provides an in-
triguing link between the role of APOE, a lipid trans-
porter, and the initiation of pathology. Mouse models
also hinted that APOE has an effect through disrupting
mitochondrial respiration, specifically in neurons [95].
SORL1 is also an AD risk factor, with homozygosity of
risk variants showing increased risk for disease progres-
sion. Young et al. [91] investigated the effects of SORL1
variants on neurotrophin response in iPSC-derived neu-
rons. Possession of a risk genotype abrogated the induc-
tion of SORL1 expression in response to brain-derived
neurotrophic factor (BDNF). This lack of induction of
SORL1 expression further led to no change in Aβ40 in
response to BDNF, whereas Aβ40 was reduced in control
cells. This study therefore places SORL1 as a crucial
intermediate between BDNF signalling and reduced Aβ
expression, a pathway inhibited by SORL1 risk SNPs.
Stem cells have been generated from patients with
copy number variations (CNVs) for the risk factor CR1
(complement receptor 1) and, based on CR1 function in
the immune system, it will be interesting to learn the
consequences of CR1 CNVs in differentiated cell types,
such as immune cells versus neurons [93].
These studies demonstrate the power of stem cell tech-
niques, whereby known genetic risk factors can be investi-
gated, but also undefined mutations and risk factors can
be modelled from patients with sporadic disease.
Three-dimensional iPSC-neuronal models of AD
The use of 3D iPSC-derived organoids is now being rea-
lised for research into dementia.
From a pathological perspective, 3D neuronal tissues
have internal ventricles as well as many interneuronal
spaces, something 2D cultures lack. Further, media
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changes in 2D cultures will remove proteins secreted by
cells, such as Aβ peptides, which will affect their ability
to form aggregates. However, organoids or matrix-
embedded 3D cultures retain them within their 3D
structure, increasing the local concentration of proteins
and potentially increasing the likelihood of pathological
aggregates [78].
Elevated levels of extracellular Aβ and intracellular
phosphorylated tau were demonstrated in neurons differ-
entiated from neural stem cells overexpressing both fAD-
associated mutant PSEN1 (ΔE9) and APP (K670N/M671L
plus V717I) [79]. Differentiated cells were cultured in
either 2D adherent cultures or embedded into matrigel to
generate 3D cultures. The authors were able to show
Aβ40 aggregates in 3D as well as phosphorylated, insol-
uble, silver-positive tau aggregates for the first time that
were confirmed as tau filaments via electron microscopy.
These aggregates were present specifically in 3D cultures
and not 2D cultures of the same cells. Treatment of the
organoids with β- and γ-secretase inhibitors reduced Aβ
and also insoluble tau, and GSK3β inhibitors were able to
reduce phosphorylated tau, demonstrating the suitability
of 3D models for drug discovery studies.
Raja and colleagues used generated 3D organoids,
using a protocol described by Kadoshima and colleagues,
to investigate pathological processes in the absence of
overexpression in cells from patients with APP duplica-
tions and M146I and A264E PSEN1 mutations [96, 78].
Amyloid deposition was apparent after 60 days of cul-
ture, with increased levels at day 90. An increase in
hyper-phosphorylated tau (pS396) between fAD orga-
noids and controls became apparent after 90 days in cul-
ture. Both amyloid deposition and hyper-phosphorylated
tau were reduced via treatment with β- and γ-secretase
inhibitors [78]. Encouragingly, the enlarged endosome
phenotypes witnessed in 2D studies [64, 67, 71] was re-
capitulated in this study, reinforcing the findings in both
paradigms. The development of bona fide neurofibrillary
tangles in the absence of overexpression of one or more
mutated genes has yet to be described. This is likely due
in part to the fact that tangle formation occurs over ex-
tended time-periods not reflected by cell culture models.
It is also worth considering that cell culture models may
not reflect the diversity of tau isoforms seen in the adult
brain (discussed further below) and the necessity of this
to the development of tau pathology is not known. Fur-
ther, although tau hyperphosphorylation is a pathological
feature, tau is also highly phosphorylated during early
development and these fetal-like cells may be resistant
to tangle formation [97, 98]. The development of in vitro
human models that more accurately recapitulate plaque
and tangle pathologies seen at post-mortem will be a
major step forward for the field; however, these early-
stage models also provide an attractive opportunity to
understand the earliest pathological changes to tau and
the sequence of events leading to the tangle pathology
observed at post-mortem. Further, several groups have
now reported a dissociation between tangle formation
and neurodegeneration [99, 100], so the absence of tau
tangles does not prohibit the study of tau-associated
disease mechanisms.
In addition to fAD, sAD patient-derived iPSCs have
been used for 2D and 3D models. Treatment with γ- and
β-secretase inhibitors was shown to reduce Aβ secretion
levels. Interestingly, in one sAD patient no decrease in
Aβ42 was seen in response to β-secretase inhibition, hint-
ing at patient variability in sAD. Also, identical inhibitor
concentrations showed differing efficacy in 2D and 3D
sAD cultures, which has important implications for drug
discovery between the two models [101].
In a direct comparison, the phosphorylation and
activation of p21-activated kinases (PAKs) in response to
exogenous Aβ was witnessed in 3D organoids and not in
2D iPSC-derived neurons. This was in addition to down-
stream cytoskeletal changes. This finding reinforces the
notion that Aβ displays local accumulation in 3D
cultures leading to more representative pathological
changes [102].
These studies point to the relevance of 3D models of
AD, both recapitulating some of the findings from 2D
studies as well as showing aggregated tau for the first
time (albeit after its overexpression). Organoids can also
be employed to investigate complex events that are in-
accessible in 2D, for example the spatial relationship
between tau and amyloid and the spread of protein
conformation through a structure.
iPSC models of frontotemporal dementia linked to
mutations in MAPT
Mutations in the tau gene, MAPT, are causative for fron-
totemporal dementia (FTD) with tau pathology. Although
mutations in MAPT do not cause AD, there is a high level
of correlation between tangle burden and disease severity,
together with compelling evidence from experimental
models demonstrating that tau mediates amyloid toxicity
[75]. Thus, a discussion of recent efforts to model tau
mutations using iPSC-neurons is warranted here. To date,
more than 40 mutations in MAPT linked to FTD have
been described, the majority of which are clustered
around the C-terminal half of the protein, within or close
to the microtubule-binding region. Thus, it is hypothe-
sised that mutations may either disrupt the binding of tau
to microtubules or promote its propensity to form aggre-
gates, two possibilities that are not mutually exclusive.
Tau splicing in iPSC-neurons
The alternative splicing of the MAPT gene leads to the
production of six protein isoforms of tau, differing by
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the presence of zero, one or two N-terminal repeats
(0 N, 1 N or 2 N) and three or four microtubule binding
repeats at the C-terminus (3R or 4R) [103–105]. Tau
splicing is developmentally regulated; only the smallest
tau isoform (0N3R) is expressed during foetal develop-
ment, but all six isoforms are expressed postnatally, with
approximately equal levels of 3R and 4R tau [103]. Tau
splicing is tightly controlled and appears to be critical for
neuronal health. A subset of MAPT mutations disrupt tau
splicing, generally leading to an increase in 4R tau [106,
107]. An over-representation of 4R tau is also observed in
the sporadic tauopathies progressive supranuclear palsy
and corticobasal degeneration [108]. The mechanisms by
which altered tau splicing can lead to disease remain
poorly characterised but may relate to an increased
propensity of 4R tau to aggregate, or altered microtubule
dynamics leading to changes in axonal transport [109].
One important opportunity offered by iPSC-neurons in
this regard is their ability to accurately reflect the complex
expression and splicing of tau seen in the adult human
central nervous system, something that is not recapitu-
lated in rodent and other animal models. However, this
has proved to be challenging due to the relative immatur-
ity of neurons derived from iPSCs. Genome-wide tran-
scriptomics studies have demonstrated that iPSC-neurons
closely resemble foetal neurons in the context of gene
expression profiles [26]. This also holds true for tau ex-
pression and splicing, where several studies have demon-
strated that 0N3R (foetal) tau is the predominant tau
isoform expressed in iPSC-neurons [110–113]. Although
after extended in vitro culture periods iPSC-neurons initi-
ate expression of multiple tau isoforms, this appears to re-
quire between 150 and 365 days in culture, which is
prohibitive for routine experimental use [110, 112]. These
findings have important implications for disease model-
ling. Several coding mutations commonly used for in vitro
and in vivo disease modelling, such as P301L and P301S,
are located within the alternatively spliced exon 10. Thus,
extended culture periods would be required in order for
the mutant protein to be expressed at high levels. As dis-
cussed below, methods now exist to accelerate in vitro
cortical differentiation from 100 days to 16 days [20], and
promote accelerated aging in cultured neurons [114, 115],
although it has not yet been assessed if any of these ap-
proaches will accelerate mature tau splicing. However,
transplanting human neurons into mouse brain leads to a
rapid maturation and expression of 3R/4R tau at a 1:1
ratio—as observed in adult human brain—at 8 months
post-transplantation [116]. Interestingly, these chimaeric
models also demonstrate the specific vulnerability of hu-
man neurons to Aβ, although it is yet to be determined if
this is mediated by tau [116].
In spite of these challenges, numerous reports now
describe successful modelling of tauopathy in iPSC-
neurons with MAPT mutations. Intronic mutations in
MAPT such as IVS 10 + 14 and 10 + 16, together with
coding mutations known to alter tau splicing, such as
N279K, are able to override the developmental regula-
tion of tau splicing, leading to the expression of 4R tau
isoforms at early time points in vitro in iPSC-derived
cortical neurons [110–113]. This appears to have an
effect on neuronal function, leading to a more rapid ac-
quisition of electrical maturity [112]. Given that differen-
tiation protocols closely mimic in vivo development, this
raises the intriguing question of the relevance of these
findings to development in utero. Could neuronal devel-
opment and functional connectivity be altered even in
early development? The early presence of 4R tau also
presents with increased cellular stress in N279K neural
stem cells, as determined by the increased presence of
the stress granule markers G3BP and TIA-1, together
with altered intracellular vesicle composition as identi-
fied by increased levels of the endosomal markers
flotilin-1 and EEA1 [111].
Modelling tau coding mutations in iPSC-neurons
Despite the aforementioned challenge of obtaining neu-
rons expressing the mature complement of tau isoforms,
iPSC models of MAPT coding mutations present in ubi-
quitously expressed exons have given mechanistic in-
sights into disease. R406W mutation neurons (together
with IVS 10 + 14 neurons) exhibit increased aggregation
of tau when analysed by dot-blot and conformation-
specific antibodies to misfolded tau [113]. R406W and
IVS 10 + 14 mutation neurons were also more suscep-
tible to calcium-induced cell death, a feature reversed
via inhibition of calcium influx [113].
In spite of a predominance of 3R tau, successful mod-
elling of the exon 10-located mutation P301L has also
been demonstrated. An early electrical maturation was
observed in neurons bearing this mutation, similar to
that seen in N279K neurons. This is particularly interest-
ing given that the relative expression of mutant tau
would be quite low and suggests that just a small
amount of mutant tau protein may be able to induce
FTD-associated cellular phenotypes [112].
Modelling tau aggregation in vitro has been a longstand-
ing challenge, in part due to its high solubility under
physiological conditions. A notable absence from iPSC-
neurons is the presence of bona fide tau tangles. This is
perhaps unsurprising given the solubility of tau protein
and the relatively short time periods iPSC-neurons are
cultured for. Verheyen and colleagues were able to induce
tau aggregation in iPSC-neurons using transfection of pre-
assembled fibrils [117]. Further, silver-positive, insoluble
tau aggregates were generated in a 3D model of AD,
although it should be noted this was in the context of
APP and PSEN1 overexpression [79].
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The tau transmission hypothesis was also studied
using control iPSC-derived neurons and exogenous tau
species [118]. Oligomeric tau species were able to tem-
plate endogenous tau to form insoluble aggregates, lead-
ing to neurite retraction, synaptic loss and calcium
signalling imbalance. Importantly, these features were
particular to oligomeric tau and not monomeric tau,
hinting at the toxic species in vivo. Reinforcing this,
iPSC-neuronal conditioned media was shown to contain
tau in an activity-dependent manner [119] and extracel-
lular tau was shown to be taken up by recipient neurons,
demonstrating an ability of tau to be transmitted
between neurons.
Modelling tau risk variants in iPSC-neurons
Recently, the tau A152T mutation was identified as a rare
variant that increases risk of tauopathies within the FTD
spectrum [120–122]. The molecular mechanisms linking
this variant to neurodegeneration have been investigated
using heterozygous and homozygous iPSC, both patient-
derived and genome-engineered. This work has revealed a
variety of cellular phenotypes, including an upregulation
in tau protein associated with A152T, demonstrated by
western blotting and mass spectrometry [123]. This is ac-
companied by an increase in tau phosphorylation at mul-
tiple disease-associated epitopes and a decrease in tau
solubility. Importantly, in spite of these changes, neurons
were negative for Thioflavin S, supporting the idea that
iPSC-neurons model pre-tangle changes to tau. A separate
study showed that A152T neurons, together with 10 + 16
FTD neurons, display increased levels of the matrix
metallo-proteases MMP2 and MMP9 as a result of activa-
tion of the ERK pathway [124]. Further, inhibition of
MEK, the upstream activator of ERK, reduced MMP9
expression and alleviated neuronal death [124].
Understanding tau–Aβ interactions
It has proven difficult to generate in vivo models that re-
capitulate the formation of plaques, tangles and neuronal
death, with rodent models typically relying on the over-
expression of multiple mutant genes to generate both
pathologies [125]. iPSC-neurons therefore provide an at-
tractive tool to dissect tau–Aβ interactions in a human
neuronal system. As discussed earlier, iPSC-neurons
from fAD patients show increased levels of phosphory-
lated tau [123], and two groups have shown a link be-
tween APP mutations and higher tau protein levels,
suggesting a previously unidentified link between APP
metabolism and tau proteostasis [71, 75]. Although tau
hyperphosphorylation, increased insolubility and mislo-
calisation have all been described in iPSC-neurons, the
development of tau silver-positive filaments has only
been achieved in the context of overexpressed mutant
APP and PSEN1 [79].
Intriguingly, a recent report generated chimeric
models of human neurons transplanted into an AD
mouse model to investigate the susceptibility of human
cells to Aβ. The human neurons showed significant
neurodegeneration, in contrast to mouse neurons, which
were unaltered in number. Interestingly, the authors
detected early markers of tau pathology such as MC1
immunoreactivity, but no overt tangle formation, sug-
gesting a dissociation between tangles and neuronal
death as suggested previously [99, 100, 116].
It remains be determined whether the crucial role of
tau in neurodevelopment will protect immature neurons
from the development of all features of tau pathology.
The use of gene editing technologies such as CRISPR
will permit the development of tau knockout iPSCs to
test whether tau is essential to amyloid toxicity in
human neurons, as has been shown previously in animal
models [126, 127].
Non-neuronal cell types
This review has focussed predominantly on neuron and
astrocyte models of AD as these are the cell types that
have been most extensively studied to date. However, it
is clear that other cell types are implicated in pathogen-
esis, most notably microglia for their the role together
with neuroinflammation in AD risk and disease progres-
sion. The identification of genetic polymorphisms in
genes enriched in microglia (brain resident macro-
phages) provides compelling evidence for the involve-
ment of this cell type in AD pathogenesis.
Rare mutations in the TREM2 gene lead to the bone
condition Nasu Hakola disease. Heterozygous mutations,
however, have been shown to increase AD risk by one-
third [89]. It is believed that the cell surface TREM2
protein functions in phagocytosis and cell signalling.
Work on the molecular basis of disease is on-going.
Genome-wide association studies have also identified
polymorphisms in CR1, CD33 and MS4A, genes
enriched in microglia, that increase risk of AD [128]. In
addition to genetic evidence, an increase in activated
microglia is observed in AD pathological tissue sur-
rounding amyloid plaques, and experimental evidence
showing microglial ablation halts tau propagation [129].
Thus, the development of human iPSC-derived micro-
glial models is warranted to further understand the
contribution of this cell type to disease [130].
Initial studies are now being reported demonstrating
iPSC-derived microglial-like cells [131, 132]. Due to the
fact that microglia develop through the haematopoietic
lineage and migrate into the neural tube before the
blood–brain barrier forms, specific differentiation strat-
egies are required. After the specification of haematopoi-
etic progenitors expressing CD34 and CD43, granulocyte
macrophage colony stimulating factor (GM-CSF) triggers
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microglial-like specification and expression of markers
such as IBA1 and CD11b. iPSC-derived microglia respond
to Aβ and oligomeric tau by upregulating AD-associated
genes, such as TREM2, CD33, MS4A and APOE [133].
Impairment of the blood–brain barrier has also been
implicated in AD progression [134]. The generation of
vascular endothelial cells and pericytes from iPSCs
would aid our understanding of the blood–brain barrier
in AD and protocols to develop these cell types have
also progressed in recent years [135, 136]. Together with
astrocytes and neurons, pericytes and endothelial cells
have been shown to generate a blood–brain barrier
model amenable to drug permeability screening [137].
The development of complex models, incorporating
multiple cell types in isolation and combination, will be
important for our understanding of AD mechanisms.
Due to the diverse developmental origins of microglia,
pericytes and endothelial cells, these lineages are not
present in 3D cortical organoid cultures. Of these cell types,
iPSC-derived microglia have been added to 3D cultures,
showing integration, migration and maturation [131, 133].
Challenges
Addressing foetal characteristics in iPSC-derived neurons
A major drawback of using iPSC-derived neurons for
AD research (in both 2D and 3D paradigms) is repre-
sented by the relative developmental age of the neurons.
As differentiation pathways mirror developmental tim-
ing, 100-day protocols generating cortical neurons in
vitro represent a foetal developmental stage [26], as ex-
emplified by tau splicing mentioned above [110–113].
This represents a significant hurdle when investigating
diseases where the single most significant risk is ageing
and whereby disease onset typically initiates after the
fifth decade of life.
One challenge is the neuronal versus glia bias due to
the later stage gliogenic switch [24]. As a consequence,
in vitro cultures are not representative of brain due to a
reduced proportion of astrocytes [138]. This will have
implications on neuronal maturity [139] as well as non-
cell autonomous disease mechanisms (for a review of
astrocytes’ role in AD see [140]).
A handful of studies have now attempted to address
this. The first used overexpression of the mutant Lamin
A gene, known to lead to the premature ageing disease
progeria [114]. Progerin overexpressing iPSC-derived
dopaminergic cells expressed epigenetic marks of ageing
and displayed hallmarks of Parkinson’s disease that were
absent in control cells. The second study made use of
direct reprogramming techniques, whereby fibroblasts
are transdifferentiated into neurons without passing
through a proliferative stage [141]. This process lacks
the pluripotent stage and so erasure of epigenetic marks
does not occur. For this reason, when iNs (induced
neuron) were compared to iPSC-derived neurons, gen-
etic signatures of ageing were maintained and ageing-
associated reductions in nuclear–cytoplasmic transport
were evident. Pharmacological inhibition of telomerase
during stem cell maintenance and early differentiation
time points was also shown to increase aging features
and disease-associated marks in iPSC-derived neurons
[115], including reduced dendrite number, increased
DNA damage and increased ROS.
Concurrent with inducing ageing in cells in culture,
cell proliferation can be manipulated and inhibited.
Strategies such as inhibition of Notch signalling can pre-
vent cell division and initiate terminal differentiation
[44]. These strategies shorten differentiation protocols,
however, as they rely on inhibition of γ-secretase, and
careful consideration is required in an AD research set-
ting. In 3D, these strategies are yet to be fully investi-
gated, although initial reports suggest Notch inhibitors
can enhance neuronal maturity [45].
These studies have been performed on 2D cultures but
could also be applied to 3D cultures. However, this will
be more technically challenging due to the inability to
treat all cells within the 3D structure. Studies such as
these will help to tease apart the deficiencies that under-
lie disease mechanisms and the ageing process that leads
to a breakdown of cell coping pathways, two processes
which when combined lead to neurodegeneration.
Variability—gene editing
Variability between iPSC clones from the same individ-
ual, and iPSCs from different individuals, remains the
major hindrance of iPSC technology (reviewed in [142]).
Generating enough statistical power through numbers of
cell lines is problematic. Therefore, careful selection of
control lines to which patient-derived cultures can be
compared is crucial. The use of unaffected siblings or
family members as control lines goes some way to re-
duce the variable genetic landscape between cell lines in
a given study via reducing allelic discrepancies. Indeed,
several studies have been able to employ cell lines from
discordant (affected versus unaffected) monozygotic
twins in iPSC-neurodegenerative research [143–145].
The benefit of such studies is that the genome is identi-
cal except for the changes in disease contraction.
Making use of the two cell endogenous repair path-
ways for DNA lesions, namely non-homologous end
joining (NHEJ) and homology directed repair (HDR),
gene editing is now possible in iPSCs (reviewed [146]).
Endonucleases are targeted to specific sites in the
genome via protein DNA-binding domains or guide
RNAs, examples of which include zinc finger nucleases
[147, 148], TALENs [149] and CRISPR/Cas9 [150, 151].
The CRISPR/Cas9 system benefits from being encoded
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by short guide RNAs rather than engineered proteins,
simplifying experimental design considerably.
Subsequent cleavage events via the fused endonuclease
can then lead to either incomplete repair by NHEJ, lead-
ing to gene knockout via frameshift mutations, or repair
by HDR via template DNA supplied to the reaction to
incorporate the intended genome changes. The first
strategy leads to knockouts with relative ease, whereas
the second can repair mutations or incorporate new
tags, mutations or longer coding cassettes with lower
efficiency. Several groups have already harnessed this
approach to generate isogenic dementia mutation lines
[67, 76, 79, 152], and genome engineering will be particu-
larly powerful for the assessment of genetic risk variants,
where multiple genes of low effect can be engineered in a
controlled way on an isogenic background.
These techniques enable the generation of isogenic
controls, whereby the genomic landscape of control and
test iPSC lines are identical except for the mutation or
knockout of interest. These technologies will go a long
way to reduce variability and will become more and
more commonplace in iPSC-research into neurodegen-
eration as the technology becomes more accessible.
Future perspectives and challenges
iPSC-derived neurons offer a revolutionary new angle on
research into dementia. iPSCs offer a limitless supply of
human neurons that are electrically active and represent
the cell type that degenerates early in AD. The fact that
these cells are morphologically, electrically and transcrip-
tionally similar to human cortical neurons in the brain
offers huge benefits to AD research. Additionally, as the
iPSCs are patient-derived, mutations, SNPs and CNVs can
be studied in the neurons in vitro. It remains difficult to
model sAD via this approach; however, similar pathways
are being implicated in multiple studies, including en-
larged endosomes, ROS damage and synaptic toxicity.
A number of drawbacks are present to the field. Vari-
ability between cell lines necessitates large numbers of
independent replicates, both biological and experimen-
tal. The gene-editing technologies now available to re-
searchers offer a solution to this, although this is still a
non-trivial first technical step to a project. The other
major drawback is biological ageing, whereby an ageing
setting is hard to recapitulate in vitro. This remains a
major hurdle to the field; however, it can be turned into
a strength as the underlying cellular deficiencies can be
studied free from widespread changes secondary to the
disease-initiating factors. Specifically, the direct effects
of mutations and risk variants can be investigated free
from late-stage, complex changes that result from a dev-
astating cellular environment of neurodegeneration.
These underlying pathways—which only manifest in an
aging setting due to reduced cellular coping mechanisms
or an accumulation of damage—can therefore be investi-
gated directly and may become the basis of strategies to
reverse degeneration early in disease progression.
The use of 3D iPSC-derived neuronal cultures will cer-
tainly complement the field. Some pathological changes are
now shown to be higher in 3D cultures compared to 2D
cultures, and the complexity of 3D organoids (both in tis-
sue architecture and cell types) will add insights into com-
plex events such as spread of pathology and cell behaviour.
The benefits of both 2D and 3D platforms have been
shown in the field of drug discovery, whereby responses
to β- and γ-secretase inhibitors, as well as other drugs,
have been shown to impact APP processing and down-
stream effects on tau. These platforms may prove invalu-
able in future in vitro screens prior to human trials,
especially for novel pathway hits, and may even be used
to stratify patients’ personalised medicine.
Conclusions
The AD field is set for an explosion of new information
gleaned from stem cell biology. Understanding the earliest
events in dementia and the direct molecular effects of
fAD mutations and genetic risk variants and providing a
human neuronal platform for drug screening are strengths
that iPSC technology can add to the field. Although
several hurdles remain, in concert with other models of
AD, iPSC models look set to make a valuable contribution
to efforts to develop novel treatments for AD.
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